Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: A nested case-control analysis

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Hsu, Chien Yi ^b,e,f   Su, Yu Wen ^a,b   Chen, Yung Tai ^b,d   Tsai, Shih Hung ^c   Chang, Chun Chin ^a,b   Li, Szu Yuan ^a,b   Huang, Po Hsun ^a,b   Chen, Jaw Wen ^a,b   Lin, Shing Jong ^a,b,e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aortic aneurysm; Diabetes mellitus; Oral antidiabetic drugs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR;

ADULT; AGE; AGED; AORTA ANEURYSM; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; RETROSPECTIVE STUDY; RISK FACTOR; SEX; TAIWAN; URBANIZATION; AORTIC ANEURYSM; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; MIDDLE AGED; ODDS RATIO; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AORTIC ANEURYSM; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84984822463     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0447-9     Document Type: Article

References (30)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm detection and management (ADAM) veterans affairs cooperative study group. Ann Intern Med. 1997;126:441-9.
2. Iribarren C, Darbinian JA, Go AS, Fireman BH, Lee CD, Grey DP. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol. 2007;17:669-78.
3. Baumgartner I, Hirsch AT, Abola MT, Cacoub PP, Poldermans D, Steg PG, et al. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the reduction of atherothrombosis for continued health (REACH) registry. J Vasc Surg. 2008;48:808-14.
4. Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010;52:539-48.
5. Kuivaniemi H, Platsoucas CD, Tilson MD 3rd. Aortic aneurysms: an immune disease with a strong genetic component. Circulation. 2008;117:242-52.
6. Sidloff D, Stather P, Dattani N, Bown M, Thompson J, Sayers R, et al. Aneurysm global epidemiology study: public health measures can further reduce abdominal aortic aneurysm mortality. Circulation. 2014;129:747-53.
7. Sohrabi S, Wheatcroft S, Barth JH, Bailey MA, Johnson A, Bridge K, et al. Cardiovascular risk in patients with small and medium abdominal aortic aneurysms, and no history of cardiovascular disease. Br J Surg. 2014;101:1238-43.
8. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes. 2005;54:2227-34.
9. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125-32.
10. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. 2013;167:451-7.
11. Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM, Kotamraju S. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64:2028-41.
12. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, et al. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis. 2010;210:51-6.
13. Bao W, Morimoto K, Hasegawa T, Sasaki N, Yamashita T, Hirata K, et al. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J Vasc Surg. 2014;59:1098-108.
14. Lu HY, Huang CY, Shih CM, Chang WH, Tsai CS, Lin FY, et al. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice. PLoS ONE. 2015;10:e0121077.
15. Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175:1527-9.
16. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308:1906-14.
17. Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174:347-54.
18. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104:157-63.
19. Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015;163:663-72.
20. Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839-47.
21. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg. 2010;52(55-61):e2.
22. Bhak RH, Wininger M, Johnson GR, Lederle FA, Messina LM, Ballard DJ, et al. Factors associated with small abdominal aortic aneurysm expansion rate. JAMA Surg. 2015;150:44-50.
23. Jimenez-Trujillo I, Gonzalez-Pascual M, Jimenez-Garcia R, Hernandez-Barrera V, de Miguel-Yanes JM, Mendez-Bailon M, et al. Type 2 diabetes mellitus and thoracic aortic aneurysm and dissection: an observational population-based Study in Spain from 2001 to 2012. Medicine (Baltimore). 2016;95:e3618.
24. Lopez-de-Andres A, Jimenez-Trujillo I, Jimenez-Garcia R, Hernandez-Barrera V, de Miguel-Yanes JM, Mendez-Bailon M, et al. National trends in incidence and outcomes of abdominal aortic aneurysm among elderly type 2 diabetic and non-diabetic patients in Spain (2003-2012). Cardiovasc Diabetol. 2015;14:48.
25. Fujimura N, Xiong J, Kettler EB, Xuan H, Glover KJ, Mell MW, et al. Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg. 2016;64(46-54):e8.
26. Pirianov G, Torsney E, Howe F, Cockerill GW. Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms. Atherosclerosis. 2012;225:69-75.
27. Hiraki Y, Miyatake S, Hayashidani M, Nishimura Y, Matsuura H, Kamada M, et al. Aortic aneurysm and craniosynostosis in a family with Cantu syndrome. Am J Med Genet A. 2014;164A:231-6.
28. Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016;15:41.
29. Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015;14:129.
30. Wang SW, Huang YB, Huang JW, Chiu CC, Lai WT, Chen CY. Epidemiology, clinical features, and prescribing patterns of aortic aneurysm in Asian population from 2005 to 2011. Medicine (Baltimore). 2015;94:e1716.